Drug Approval | May 12, 2022
USFDA approves Lilly and Incyte's Olumiant to treat hospitalised patients with Covid-19
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Cipla has reported consolidated financial results for the period ended March 31, 2022
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
RNA extraction free kit to deliver results in just 45 minutes
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
The plan is to advance innovative therapies to drug-resistant cancers
Ahead of International Thalassemia Day on 8th May, medical professionals and representatives of patient bodies participated in a virtual discussion on the current situation of Thalassemia management in India
Digital PCR format allows for rapid turnaround time to facilitate fast and accurate post-transplant treatment decisions
This newly designed small-format detector is made up of caesium iodide technology and is extremely high in resolution, capable of capturing the fine detail of smaller anatomical structures present in paediatric patients
RNAstorm and DNAstorm RNA/DNA extraction kits will be sold exclusively through the Biotium website and authorized distributors
Subscribe To Our Newsletter & Stay Updated
